All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-GPC1 (AM4) h(CD28-41BB-CD3z) CAR circRNA incorporates the AM4 clone to target the heparan sulfate proteoglycan GPC1, a critical co-receptor for growth factors in pancreatic ductal adenocarcinoma. By delivering this CAR via the circRNA platform, we enable a transient therapeutic window that disrupts the oncogenic signaling pathways supported by the tumor stroma. This non-integrating approach allows for the safe targeting of GPC1-expressing cancer cells while ensuring that the host's normal tissue remodeling functions are not permanently impaired by long-term CAR-T persistence.
There are currently no customer reviews or questions for VivoCAR™ Anti-GPC1 (AM4) h(CD28-41BB-CD3z) CAR circRNA (XS-1225-YX119). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION